Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial

18Citations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-Term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400mg twice daily at Day 1 then 400mg once daily from Day 2 to Day 10.We aimto evaluate this in the C-20-15 DisCoVeRy trial.

Cite

CITATION STYLE

APA

Le, M. P., Peiffer-Smadja, N., Guedj, J., Néant, N., Mentre, F., Ader, F., … Peytavin, G. (2020). Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. Journal of Antimicrobial Chemotherapy, 75(9), 2376–2380. https://doi.org/10.1093/jac/dkaa191

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free